Stock Scorecard
Stock Summary for SIGA Technologies Inc (SIGA) - $8.56 as of 3/28/2024 10:03:46 PM EST
Total Score
21 out of 29
Currently on the following lists
Growth Stock List
Tim's Recommendation
Buy
Growth List Algorithm Criteria for SIGA
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SIGA
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SIGA
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for SIGA
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for SIGA
Financial Details for SIGA
Company Overview |
|
---|---|
Ticker | SIGA |
Company Name | SIGA Technologies Inc |
Country | USA |
Description | SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 8.56 |
Last Day Price Updated | 3/28/2024 10:03:46 PM EST |
Last Day Volume | 1,231,489 |
Average Daily Volume | 872,458 |
52-Week High | 8.57 |
52-Week Low | 3.93 |
Last Price to 52 Week Low | 117.81% |
Valuation Measures |
|
Trailing PE | 8.76 |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | 2.53 |
Free Cash Flow Ratio | 4.06 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 4.42 |
Total Cash Per Share | 2.11 |
Book Value Per Share Most Recent Quarter | 2.77 |
Price to Book Ratio | 3.02 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 4.23 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 71,092,000 |
Market Capitalization | 608,547,520 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | 3/25/2024 |
Last Dividend Amount | 0.45 |
Current Dividend Amount | 0.60 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 1.05 |
Trailing Annual Dividend Yield | 12.35% |
Forward Annual Dividend Rate | 1.05 |
Forward Annual Dividend Yield | 12.35% |
5-Year Dividend Payments Count | 3 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | 110.53% |
Income Statement |
|
Quarterly Earnings Growth YOY | 272.10% |
Annual Earnings Growth | 100.76% |
Reported EPS 12 Trailing Months | 0.95 |
Reported EPS Past Year | 0.96 |
Reported EPS Prior Year | 0.46 |
Net Income Twelve Trailing Months | 68,068,828 |
Net Income Past Year | 68,068,826 |
Net Income Prior Year | 33,904,806 |
Quarterly Revenue Growth YOY | 926.00% |
5-Year Revenue Growth | -21.75% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 150,145,844 |
Total Cash Past Year | 150,145,844 |
Total Cash Prior Year | 98,790,622 |
Net Cash Position Most Recent Quarter | 150,145,844 |
Net Cash Position Past Year | 150,145,844 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 196,858,907 |
Total Stockholder Equity Prior Year | 170,160,042 |
Total Stockholder Equity Most Recent Quarter | 196,858,907 |
Options |
|
Put/Call Ratio | 0.04 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.79 |
MACD Signal | 0.41 |
20-Day Bollinger Lower Band | 3.71 |
20-Day Bollinger Middle Band | 5.61 |
20-Day Bollinger Upper Band | 7.51 |
Beta | 0.86 |
RSI | 87.62 |
50-Day SMA | 5.29 |
200-Day SMA | 6.73 |
System |
|
Modified | 3/27/2024 6:38:29 AM EST |